Chest ACCP Member Benefits
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Guest Access | Sign In via User Name/Password
This Article
Right arrow Full Text (PDF) Free
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Article Archive
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Amyes, S. G. B.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Amyes, S. G. B.
(Chest. 1998;113:228S-232S.)
© 1998 American College of Chest Physicians

Strategies and Options for Minimizing Resistance Emergence in Pulmonary Infections

Sebastian G. B. Amyes DSc1

1 From the Department of Medical Microbiology, The Medical School, University of Edinburgh, Scotland

The early-onset hospital pulmonary Gram-negative infections may respond to ciprofloxacin and co-amoxiclav without significant resistance development. Penicillin-resistant Streptococcus pneumoniae may be treated with macrolides, fluoroquinolones, and glycopeptides. The late-onset hospital pathogens all seem to have developed resistance to cephalosporins, so greater reliance is now made on the fluoroquinolones and carbapenems when aminoglycoside therapy is considered undesirable.






HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 1998 by the American College of Chest Physicians.